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Abstract
Circulating nucleic acids (CNAs) are under investigation as a liquid biopsy in cancer. However there is wide variation
in blood processing and methods for isolation of circulating free DNA (cfDNA) and microRNAs (miRNAs). Here we
compare the extraction efficiency and reproducibility of 4 commercially available kits for cfDNA and 3 for miRNA
using spike-in of reference templates. We also compare the effects of increasing time between venepuncture and
centrifugation and differential centrifugation force on recovery of CNAs. cfDNA was quantified by TaqMan qPCR and
targeted deep sequencing. miRNA profiles were assessed with TaqMan low-density arrays and assays. The
QIAamp® DNA Blood Mini and Circulating nucleic acid kits gave the highest recovery of cfDNA and efficient recovery
(>90%) of a 564bp spike-in. Moreover, targeted sequencing revealed overlapping cfDNA profiles and variant depth,
including detection of HER2 gene amplification, using the Ion AmpliSeq™Cancer Hotspot Panel v2. Highest yields of
miRNA and the synthetic Arabidopsis thaliana miR-159a spike-in were obtained using the miRNeasy Serum/Plasma
kit, with saturation above 200 µl of plasma. miRNA profiles showed significant variation with increasing time before
centrifugation (p<0.001) and increasing centrifugation force, with depletion of platelet associated miRNAs, whereas
cfDNA was unaffected. However, sample replicates showed excellent reproducibility on TaqMan low density arrays
(ρ = 0.96, p<0.0001). We also successfully generated miRNA profiles for plasma samples stored > 12 years,
highlighting the potential for analysis of stored sample biobanks. In the era of the liquid biopsy, standardisation of
methods is required to minimise variation, particularly for miRNA.
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Introduction
There is wide interest in the utility of circulating nucleic acids
(CNAs) as biomarkers of cancer. Thus far, the majority of
research has focussed on circulating cell-free DNA (cfDNA)
due to its stability and ease of isolation. Increasing quantities
are found in cancers compared to healthy controls, with high
levels sometimes in excess of 100 ng/ml detected in advanced
disease [1].
So far there has been no standardisation of methods for
cfDNA isolation, making comparison between different studies
and markers difficult. In addition, recent studies have correlated
a large proportion of tumour-specific aberrations with low-
molecular weight fractions of cfDNA [2,3]. This highlights the
need for optimum protocols for extraction of cfDNA to ensure
minimal contamination by high-molecular weight DNA
fragments from stromal, inflammatory, and mononuclear cells
[4], that might influence downstream analyses such as deep
sequencing.
Circulating microRNAs (miRNAs) are also increasingly under
investigation [5]. These miRNAs are small regulatory
molecules, which function as negative regulators of target
genes by directing specific mRNA cleavage or inhibition of
translation. There are 2,042 mature human miRNAs described
in miRBase V19 (http://www.mirbase.org/) and miRNA
sequences are being integrated with deep sequencing data [6].
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Recent studies have identified tumour–associated miRNAs,
elevated in plasma of cancer patients [5,7] and have shown
that these are stable, protected from endogenous RNAse
activity [8] in micro-vesicles [9], and are also well preserved in
formalin-fixed paraffin embedded (FFPE) tissues.
A number of methods have been used to isolate cfDNA from
plasma, ranging from simple boiling [10], SDS/Proteinase K
digestion and phenol/chloroform extraction, to commercially
available small-scale column-based extraction kits and
magnetic bead technology. In our previous studies of cfDNA in
patients with breast cancer, we have routinely used the
QIAamp® DNA Blood Mini Kit for isolation of cfDNA [11-14].
Similarly, there are an increasing number of commercial kits
marketed for isolation of miRNA.
The aim of this study was to investigate the effects of pre-
analytical processing on isolation of CNAs from plasma, and
also to compare the extraction efficiency, yield and
reproducibility obtained using commercially available kits using
spike-in of reference templates. We compared 4 kits for cfDNA
isolation (QIAamp® DNA Blood Mini, QIAamp® Circulating
Nucleic Acid Kit, NucleoSpin® Plasma XS kit and FitAmp®
Plasma/Serum DNA Isolation kit), and 3 kits for miRNA
isolation (miRvana microRNA Isolation kit, miRNeasy Serum/
Plasma kit and QIAamp® Circulating Nucleic Acids kit). Yields
of cfDNA and miRNA and recovery of spike-in references
varied widely between the different kits. miRNA yield was
significantly affected by both centrifugation of plasma at
10000g, which depletes platelets and leaving blood at room
temperature for > 2 hours, whereas cfDNA was unaffected.
Moreover, sequencing of cfDNA samples with Ion
AmpliSeq™Cancer Hotspot Panel v2 recovered using the “top
2” kits showed no significant difference in the coverage of the
207 amplicons in the panel. Finally, we suggest standard
approaches for optimum blood processing and isolation of
cfDNA and circulating miRNAs.
Materials and Methods
Ethics statement
The study protocol was approved by the Riverside Research
Ethics Committee (Imperial College Healthcare NHS Trust;
REC reference number: 07/Q0401/20) and the Leicestershire,
Northamptonshire & Rutland Research Ethics Committees
(REC reference number: 05/Q2502/28; 11/EM0023). Blood
sample collection was conducted in accordance with the
Declaration of Helsinki. All patients gave written informed
consent prior to participation.
Blood processing
20 ml venous blood samples were drawn in the morning into
EDTA-containing tubes (BD Biosciences) and centrifuged at
1000g (Jouan CR422; Jouan) for 10 min at 4 °C. Plasma was
carefully removed, leaving 3-5 mm above the buffy coat, added
to a 15 ml Falcon tube (BD Biosciences) and re-centrifuged at
1000g for 10 min at 4 °C. Plasma was carefully removed and
stored at -80 °C in 1 ml aliquots in 1.5 ml tubes (Starlab) for
cfDNA, and in 1.5 ml RNase-free tubes (Starlab) for miRNA.
We also varied the speed of the second centrifugation step:
1000g, 2000g (Jouan CR422; Jouan) or 10000g (Microcentaur;
MSE) each for 10 min at 4 °C, as well as increasing the time
between venepuncture and the first centrifugation step (at 2 hr
and at 6 hr). On thawing a third and final spin was performed at
1000g for 5 min at room temperature and plasma carefully
removed into a separate tube away from any residual debris
before extraction of CNAs.
Extraction of circulating nucleic acids, spike-in
templates and QC checks
We purchased 3 plasma samples from healthy females (age
range 35 - 39 years) (Seralab) and pooled an equal volume to
generate a reference healthy plasma sample. For cfDNA we
compared isolation from 1 ml starting plasma volume, with
each sample/kit performed in triplicate, using the QIAamp®
DNA Blood Mini Kit, QIAamp® Circulating Nucleic Acid Kit,
NucleoSpin® Plasma XS Kit (Macherey-Nagel) and FitAmp®
Plasma/Serum DNA Isolation kit (Epigentek). Each extraction
was performed exactly according to manufacturers’ instructions
and as described previously [12,13]. With each sample/kit the
elution volume was 1/10th of the starting plasma volume. As
additional validation we spiked λ/HindIII DNA (Ambion) into 1
ml of the pooled healthy plasma at 4 fixed concentrations (50
ng, 5 ng, 0.5 ng and 0.05 ng) and assessed recovery of two
fragments by real-time qPCR.
Circulating miRNAs were extracted from 1 ml, 500 µl or 200
µl of plasma. As miRNA was not recovered from the pooled
healthy plasma (Seralab) we isolated miRNA from pooled
plasmas from 3 patients with either primary or metastatic
breast cancer. Each extraction was performed in triplicate,
using the miRNeasy Serum/Plasma Kit (Qiagen), miRvana
microRNA Isolation kit (Ambion) or QIAamp® Circulating
Nucleic Acid Kit (Qiagen), according to the manufacturers’
instructions. 30 pg or 30 ng of the synthetic Arabidopsis
thaliana miR-159a (ath-miR-159a; 5’-
UUUGGAUUGAAGGGAGCUCUA-3’) (Integrated DNA
Technologies) was spiked-in to each sample after the initial
lysis step to test extraction efficiency. All samples were eluted
in 50 µl of RNase-free water.
Initial QC checks of eluted cfDNA and RNA (1 µl each) were
performed using the Qubit® 2.0 dsDNA high sensitivity assay
(Life Technologies) and Agilent Bioanalyser 2100 analysis with
RNA 6000 Pico reagents and chips (Agilent), respectively,
according to manufacturers instructions..
Reverse transcription and analysis of miRNA profiles
MicroRNAs were reverse transcribed from 3 µl of sample
using the TaqMan Megaplex RT system (Applied Biosystems),
and pre-amplified from 2.5 µl of cDNA using the TaqMan
Megaplex Pre-Amp system (Applied Biosystems) according to
manufacturer’s instructions on a Veriti thermal cycler (Applied
Biosystems). Pre-amplified cDNA was diluted 1:25 prior to use
and compared with unamplified cDNA, diluted 1:5 in 1xTE
buffer. A RT-negative control was included in each experiment
to assess genomic DNA contamination, all of which showed no
amplification upon analysis by qPCR for hsa-miR-21. For
validation of the TLDA cards, pre-amplified cDNA was diluted
1:100.
Influence of Plasma Processing on Analysis of CNAs
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For miRNA PCR arrays, TLDA v2.0 cards were used
according to manufacturer’s instructions on an Applied
Biosystems 7900 thermal cycler as follows: 50 °C for 2 min,
94.5 °C for 10 min, followed by 40 cycles of 97 °C for 30 sec
and 59.7 °C for 1 min. The cycle threshold (CT) values were
determined using a fixed threshold of 0.1 for all qPCR
experiments. Exiqon miRCURY LNA Serum/Plasma focus
panels were analysed on a Roche Lightcycler 480 thermal
cycler as follows: 95 °C for 10 min, followed by 45 cycles of 95
°C for 10 sec and 60 °C for 1 min with a ramp rate of 1.6 °C/
sec.
MiRNA samples were analysed in triplicate using 3 µl of
diluted template and TaqMan microRNA assays (hsa-miR-191
(assay code 000490), hsa-miR-21 (000397), ath-miR-159a
(000338), hsa-miR-15b (000390), hsa-miR-16 (000391), hsa-
miR-24 (000402), hsa-miR-155 (002623) or hsa-miR-484
(001821) (Applied Biosystems)) according to manufacturer’s
instructions. Cycling was performed using a 10 µl reaction on a
Step 1 Plus thermal cycler: for cfDNA: 95 °C for 20 sec,
followed by 50 cycles of 95 °C for 1 sec and 60 °C for 20 sec;
for miRNA assays: 95 °C for 20 sec, followed by 40 cycles of
95 °C for 1 sec and 60 °C for 20 sec. Results were analysed
with Step 1 v2.2 software and Microsoft® Excel.
Quantitation of cfDNA and Targeted Deep Sequencing
Each sample (3.6 µl of eluted cfDNA) was quantified in
triplicate relative to a standard curve, generated from a serially-
diluted template (Human Genomic DNA; Roche) of known
concentration, and converted to ng/mL using the following
equation: (Total quantity of cfDNA/3.6) x 1000, and an in-house
locus-specific TaqMan assay targeting GAPDH [11], and two
inventoried assays for ACTBL2 (Hs001101944_s1, targeted
amplicon 67 bp) and HPRT1 (Hs03929096_g1, targeted
amplicon 64 bp) (Applied Biosystems). For the λ/HindIII DNA
spike-in experiments, two fragments (23kb and 564 bp) were
quantified using custom primers (Sigma) and FAM-MGB
probes (Applied Biosystems). The spike-in was quantified in
triplicate relative to a standard curve generated from serially-
diluted λ/HindIII DNA. Sequences were: 23 kb fragment:
forward, 5’-CGCACAGGAACTGAAGAATG-3’; reverse, 5’-
CCGTCGAGAATACTGGCAAT-3’; FAM-MGB probe, 5’-
TGTACTTTCGTGCTGTCGCGGATCG-3’ (targeted amplicon
108 bp); 564 bp fragment: forward, 5’-
TGGGATCATTGGGTACTGTGG-3’; reverse, 5’-
CAGACTTGGGGGTGATGAGTTT-3’; FAM-MGB probe, 5’-
CCGCTATCCCTGATCAG-3’ (targeted amplicon 97 bp).
For DNA sequencing, cfDNA was isolated from 1 ml plasma
of four patients with metastatic breast cancer, using two kits
(QIAamp® DNA Blood Mini Kit and the QIAamp® Circulating
Nucleic Acid Kit) to generate 8 templates. 10 ng of each
template was sequenced in pairs on two 316 chips on the Ion
PGM™ Sequencer using the Ion AmpliSeq™Cancer Hotspot
Panel v2 according to manufacturer’s instructions. DNA
sequencing data was accessed through the Torrent Suite v.
3.4.2. Reads were aligned against the human genome (hg19)
using Alignment v 3.4.48996 and variants called using the
coverageAnalysis v 3.4.51836 and variantCaller v 3.4.51874,
respectively. All raw BAM files have been deposited at the
European Nucleotide Archive (ENA - https://www.ebi.ac.uk/
ena) under accession number PRJEB4510.
Statistical analysis
All statistical analysis was performed using GraphPad Prism
6 for Windows. An unpaired Mann-Whitney test was used for
comparison of RNA extractions and a two-tailed Spearman’s
correlation analysis was used for correlation analysis of the
TLDA and miRCURY cards. Where indicated, miRNA ΔCT
values were normalised to the average CT values obtained on
the miRCURY PCR array and TLDA card A before cycle 35
[15]. A matched-paired Wilcoxon test was used to compare the
variants detected in the cfDNA sequenced on the Ion PGM™
Sequencer using the Ion AmpliSeq™Cancer Hotspot Panel v2.
Results
Recovery of cfDNA and λ/HindIII spike-in
We compared 4 commercial kits for isolation of cfDNA, using
1 ml of pooled healthy plasma. Each extraction was performed
in triplicate and each cfDNA sample was quantified in triplicate
by qPCR targeting GAPDH [13], ACTBL2 and HPRT1. The 3
assays showed equivalent results, with the QIAamp® DNA
Blood Mini and QIAamp® CNA kits giving the highest quantities
of cfDNA/ml of plasma (mean 264.28 ng/ml and 239.85 ng/ml,
respectively), 10 fold higher than the other two kits (Figure 1A).
As validation, we also performed Qubit® 2.0 analysis, which
confirmed this trend but with a slightly higher recovery of
cfDNA (Figure 1A).
To determine the efficiency of cfDNA recovery, we assessed
recovery of spiked-in λ/HindIII DNA using the 3 kits that gave
the highest yields of cfDNA (QIAamp® DNA Blood Mini Kit,
QIAamp® CNA Kit and NucleoSpin® Plasma XS Kit). The
QIAamp® DNA Blood Mini kit and the QIAamp® CNA Kit
showed similar but variable recovery of the 23kb fragment
(range 20-70%). The QIAamp® CNA Kit gave the highest yield
of the smaller (564 bp) fragment, recovering between 90 -
100% at each dilution tested; whereas the NucleoSpin® Plasma
XS Kit showed a lower recovery of both amplicons (Figure 1B).
cfDNA extraction methods generate equivalent targeted
deep sequencing data
To determine whether the two kits giving the best recovery of
cfDNA (QIAamp® DNA Blood Mini kit and the QIAamp® CNA
Kit) showed any variance in cfDNA profiles, paired cfDNA from
4 metastatic patients were sequenced using the Ion
AmpliSeq™Cancer Hotspot Panel v2 on the Ion PGM™
Sequencer. A total of 412M bases were generated across the
eight cfDNA samples, with an average of 52 ± 5 M bases per
sample (Table S1). This was equivalent to 503 ± 46K reads, >
96% of which mapped to the target region providing an
average coverage of 2000x. High similarity was observed in the
coverage profile for each cfDNA pair across the 207 amplicons
(average size 154 bp, range 111bp -187 bp) (Figure 2). Of
note, one sample (P4) showed a peak in the number of reads
(>30,000 reads) at ERBB2 suggesting gene amplification. The
total number of reads at each amplicon showed high
Influence of Plasma Processing on Analysis of CNAs
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correlation, (ρ > 0.95, p<0.001) for 3 of the 4 cfDNA pairs
(Table S1). In the one sample (P3) with lower but significant
correlation (ρ = 0.87) the QIAamp® CNA method gave a more
uniform coverage that the QIAamp® DNA Blood Mini method.
A total of 167 germline and somatic variants were called with
an average of 21 variants per sample (Table S2). 136 (81%) of
the total variants were matched in paired samples in terms of
variant position and frequency with no significant difference in
percentage variant call (p>0.05, p<0.001). Thirty-one (19%)
variants were unique, but the majority of these were in P3 and
detected at <10% depth.
Recovery of circulating miRNA
We compared 3 commercial kits for extraction of circulating
miRNA. Unfortunately, none were successful at recovering
miRNA from 1 ml of the pooled control plasma, as two miRNAs
(hsa-miR-21 or hsa-miR-191) were undetected by qPCR.
Therefore, we trialled the 3 kits using pooled plasma from 3
primary breast cancer patients recruited to our studies. There
were marked differences in recovery of miRNA between the
three kits. Bioanalyser analysis showed minor differences in
miRNA yields for the QIAamp® CNA or miRNeasy Plasma/
Serum kit; which were significantly higher than the miRvana
microRNA Isolation kit (p <0.001) (Figure 3). Considering
individual miRNAs, qRT-PCR revealed lower CT values (4 - 10
cycles earlier) for both hsa-miR-21 and hsa-miR-191 with the
miRNeasy Serum/Plasma kit compared to the QIAamp® CNA
and miRvana kits when analysing both cDNA and pre-amplified
cDNA (Figure 3A, B). The CT values for the synthetic ath-
miR-159a spike-in were also consistently lower using the
miRNeasy Serum/Plasma kit compared to the miRvana kit, but
not to the QIAamp® CNA kit (Figure 4A, B).
Of note, although the miRvana microRNA Isolation kit gave
the lowest yield of miRNAs, even from 1 ml of pooled plasma,
the profile of miRNAs detected by TLDA cards showed
significant correlation with the profile generated following
extraction of miRNA from 200 µl of plasma using the miRNeasy
Serum/Plasma kit (p <0.0001) (Figure 4C). Based on these
results, further optimisation of miRNA isolation was only
performed using the miRNeasy Serum/Plasma kit.
The yield of miRNA is not dependent on plasma volume
Next, we compared miRNA yields from 200 µl, 500 µl and 1
ml starting plasma volume. There was no significant increase in
miRNA yield with increasing plasma volume by either
Bioanalyser analysis (Figure S1) or qRT-PCR (hsa-miR-21 and
hsa-miR-191) (Figure 4D), suggesting the quantity of miRNA
recovered was not volume dependent. As part of this
experiment, we also spiked-in ath-miR-159a at a concentration
of 30 ng (1000-fold higher than in the previous kit comparisons)
to test whether this resulted in saturation of either the column
or the qPCR. Although the 1000-fold increase in concentration
of the spike-in was reflected by an appropriate CT value with
200 µl plasma volume, there was an increase in CT values (and
therefore decrease in detected concentration of the spike-in)
with increasing plasma volume, suggesting less efficient
recovery.
Pre-analytical processing alters the yield of miRNA but
not cfDNA
We obtained 15 ml blood samples from 5 healthy female
volunteers and processed 7.5 ml for plasma at 2 hours post-
venepuncture, while the remaining 7.5 ml was left for 6 hours at
room temperature before processing. Plasma was separated
using the 2 step 1000g, 1000g protocol (see methods). Both
cfDNA and miRNA were recovered in triplicate from 1 ml and
200 µl of plasma using the QIAamp® DNA Blood Mini kit and
miRNeasy Serum/Plasma kit, respectively and analysed by
Figure 1.  Comparison of cfDNA recovery using different commercially available kits.  A. Average cfDNA yield per 1 ml of
plasma with 4 extraction kits, quantified using qPCR for GAPDH, ACTBL2 and HPRT and Qubit® 2.0 High Sensitivity dsDNA Assay.
Error bar = ±SEM, n = 9 from 3 independent experiments each performed in triplicate. ND = Not detectable. B. Percent recovery of
serial dilutions of λ/HindIII DNA, quantified using assays targeting the 23 kb and 564 bp fragments. Error bar = ±SEM, n = 9 from 3
independent experiments performed in triplicate. CNA = Circulating Nucleic Acid kit.
doi: 10.1371/journal.pone.0077963.g001
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qPCR. Yields of cfDNA were not altered by blood processing
time (Figure 5A); however, 6 candidate miRNAs analysed were
significantly different, in particular, hsa-miR-15b and hsa-
miR-191 (p<0.001) (Figure 5B).
We also compared recovery of cfDNA and miRNA from 1 ml
and 200 µl of pooled plasma, respectively following
centrifugation at 1000g then either 1000g, 2000g or 10000g.
Yields of cfDNA were equivalent, as assessed by GAPDH
quantitation (data not shown); however, miRNA yield was
notably lower after centrifugation at 10000g. Following profiling
with TLDA card A, there were a total of 195 miRNAs detected
after 1000g and 187 miRNAs at 2000g, but only 138 miRNAs
detected at 10000g (Table S3). However, comparison of ΔCT
values showed significant correlation between these (Figure
5C-E), particularly between samples centrifuged at 1000g and
2000g. As expected, platelet-associated miRNAs including
hsa-miR-24, hsa-miR-191, hsa-miR-197 and hsa-miR-223 [16]
were notably reduced after centrifugation at 10000g (Table S3).
MiRNA profiles show good reproducibility between
replicate samples
To test reproducibility of the miRNA PCR arrays, we
analysed pooled samples from patients with primary breast
cancer in duplicate on both TLDA cards and the Exiqon
miRCURY LNA microRNA PCR array. Both platforms showed
high reproducibility between replicate samples (Figure S2A, B).
There was also a lower but significant correlation between
miRNA profiles on the two platforms (ρ = 0.6, p<0.0001 -
Figure S2C). Furthermore, as melt-curve analysis showed that
a number of positive probes with high CT values (>35) on the
Figure 2.  Comparison of number of reads between two different extraction kits using the Ion AmpliSeq™Cancer Hotspot
Panel v2.  Analysis of 4 plasma samples extracted using both the QIAamp® DNA Blood Mini kit and the QIAamp® CNA Kit. In each
trace, the number of reads is shown on the Y-axis. Red lines indicate the QIAamp® CNA Kit and the blue lines represent the
QIAamp® DNA Blood Mini kit. For in depth analysis see Tables S1 and S2.
doi: 10.1371/journal.pone.0077963.g002
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miRCURY LNA platform had multiple melting temperatures
(Figure S2C); further experiments were performed using the
TLDA cards only.
Recovery of miRNA from stored plasma
Our final aim was to determine whether miRNA was
recoverable from stored plasma, as we have shown previously
that cfDNA can be isolated and analysed from plasma samples
stored for > 12 years [14]. To achieve this we compared 20
plasma samples from patients with metastatic breast cancer as
two pools: 10 extracted from freshly frozen plasma and 10 from
plasma stored at -80 °C for >12 years. A total of 177 miRNAs
were detected in the stored pool, compared to 202 miRNAs in
the fresh pool (TLDA Pool A v2.0 Cards, Table S4), suggesting
some loss of miRNAs on storage. We assessed whether CT
values were lower in fresh compared to stored samples and
found no significant difference (p = 0.77). However, there was a
significant correlation of both CT and ΔCT values between
miRNAs detected in the two pools (ρ = 0.84, p<0.0001, and ρ =
0.82, p<0.0001, respectively – Figure S2D, E), suggesting
similar yield of miRNA and confirming successful recovery of
miRNA from long term stored plasma.
Discussion
There is currently no consensus protocol for pre-analytical
processing of blood for isolation of CNAs. Ideally, blood
samples should be collected into K2 EDTA tubes, kept on ice,
and processed within 2 hours of collection to ensure peripheral
blood mononuclear cells (PBMCs) do not lyse and release
either DNA or RNA, which could interfere with subsequent
analyses [17]. Published protocols for centrifugation of blood
samples typically use two sequential spins (varying from 800 -
2000 g for 10-15 min) to separate plasma from buffy coat [18].
Our group first showed that a third bench top spin (1000 g for 5
min) is necessary to pellet any remaining cells, platelets and
cellular debris [12]. Plasma and buffy coat containing PBMCs
should be aliquoted and stored at -80 °C to avoid multiple
freeze/thaw cycles. Although yields of cfDNA are reported to
decline by approximately 30% per year in storage [19], we
have successfully isolated cfDNA from plasma samples stored
at -80°C for >12 years and analysed this by SNP 6.0 Array
[14].
The findings here support previous studies [20], whereby
either time delay or storage temperature of blood before
centrifugation did not significantly affect levels of cfDNA.
However, this variation in pre-analytical processing
(centrifugation speed and time and temperature after blood
drawing) can greatly affect miRNA profiles [21-23]. We suggest
that the differences reported herein, which result from delayed
processing post-venepuncture and higher centrifugation
speeds, are largely due to altered recovery of platelets and
microvesicles. Importantly, we have shown significant
correlation between replicate samples, and with increasing
centrifugation speed, but with significant reduction in the
recovery of platelet-associated miRNAs (e.g. hsa-miR-24, hsa-
miR-191, hsa-miR-197 and hsa-miR-223 [16]) after
centrifugation at 10000g. Based on these findings, we
recommended that blood samples are processed within 2
hours of venepuncture, with centrifugation speed carefully
selected for the desired downstream analysis (i.e. platelet-rich
vs. platelet-poor plasma). We concur with McDonald et al. [22]
that future studies of circulating miRNA should explicitly state
the centrifugation protocol and blood storage time to ensure
reproducibility.
Figure 3.  Bioanalyzer analysis of circulating miRNA iolated with different kits.  A-C. Representative Bioanalyser traces of cell-
free RNA obtained from 1 ml of plasma using 3 commercial kits. The kits used and RNA integrity (RIN) values are highlighted above
the trace and representative gels are shown below each trace. A = extractions using the miRNeasy Serum/Plasma kit, B = mirVana
microRNA Isolation kit and C = Circulating Nucleic Acid kit. Quantities obtained are shown in D. Error bar = ±SEM, n = 3 from 3
independent experiments.
doi: 10.1371/journal.pone.0077963.g003
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A number of different manufacturer’s extraction kits are
available for the isolation of circulating nucleic acids. We have
shown that the chosen kit can have a profound effect on cfDNA
yield, where efficient recovery is desired for down-stream
analyses, including SNP 6.0 array [14] and deep-sequencing.
Our results from spike-in experiments illustrate that the kits
Figure 4.  qRT-PCR analysis of miRNA isolated with
different kits.  A. Average CT values obtained for hsa-
miR-191, hsa-miR-21 and ath-miR-159a on cDNA and pre-
amplified cDNA (Pre-Amp) from 1 ml of plasma. Error bar =
±SEM, n = 9 from 3 independent experiments performed in
triplicate. S/P = Serum/Plasma kit, CNA = Circulating Nucleic
Acid kit. B. Average ΔCT values comparing the miRNeasy
Serum/Plasma and CNA kit to the miRvana Isolation kit. ΔCT
values calculated using the equation: Average miRNA CT using
the miRvana kit - Average miRNA CT using another kit (i.e
miRNeasy Serum/Plasma or CNA kit). Error bar = ±SEM, n = 9
from 3 independent experiments performed in triplicate. S/P =
Serum/Plasma kit, CNA = Circulating Nucleic Acid kit. C. Two-
tailed Spearman’s correlation analysis of ΔCT values obtained
from TLDA A cards and samples extracted from 1 ml of plasma
using the miRvana Isolation kit or 200 µl of plasma using the
miRNeasy Serum/Plasma kit. Dotted lines represent the 95%
confidence interval. Rho (ρ) and p-values are indicated on the
graph. D. Average CT values obtained analysing hsa-miR-191,
hsa-miR-21 and ath-miR-159a in cDNA produced from 1 ml,
500 µl or 200 µl of plasma using the miRNeasy Serum/Plasma
kit. Error bar = ±SEM, n = 9 from 3 independent experiments
performed in triplicate.
doi: 10.1371/journal.pone.0077963.g004
Figure 5.  Recovery of cfDNA and miRNA from plasma:
effects of increasing centrifugation speed.  A. Quantitation
of cfDNA using qPCR for GAPDH. Blood was processed within
2 hr or 6 hr post-venepuncture and cfDNA isolated from 1 ml of
plasma. Whiskers of the box-plot show minimum and maximum
values. B. Comparison of miRNA profiles from plasma
processed 6 hr post-venepuncture compared to samples
processed at 2 hr. Results presented as -ΔCT (change from 2
hours. Error bar = ±Std Dev, n = 5. *p<0.05; **p<0.01;
***p<0.001. C. Two-tailed Spearman’s correlation analysis of
ΔCT values obtained from TLDA A cards for duplicate miRNA
samples following centrifugation at 1000g and 2000g. Dotted
lines represent the 95% confidence interval. D. Two-tailed
Spearman’s correlation analysis of ΔCT values obtained from
TLDA A cards for duplicate miRNA samples following
centrifugation at 1000g and 10000g. Dotted lines represent the
95% confidence interval. E. Two-tailed Spearman’s correlation
analysis of ΔCT values obtained from TLDA A cards for
duplicate miRNA samples following centrifugation at 2000g and
10000g. Dotted lines represent the 95% confidence interval.
For C - E, Rho (ρ) and p-values are indicated on each graph.
doi: 10.1371/journal.pone.0077963.g005
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tested show variable recovery of both shorter and longer DNA
fragments. Sequential fractionation has shown that low
molecular weight cfDNA fractions often harbour genetic
aberrations indicative of tumour-derived DNA [2,3]. The results
presented here show that it is possible to efficiently recover
cfDNA using commercially available kits, and targeted
sequencing demonstrated efficient recovery of low molecular
weight fractions, with detection of single nucleotide variants in
cfDNA indicative of a tumour origin. There was little difference
in recovery of cfDNA using the “top 2” kits as demonstrated by
equivalent variant depth across 207 amplicons (average size
154 bp) using the Ion AmpliSeq™Cancer Hotspot Panel v2.
Our study has highlighted that the yield of miRNA can also
vary widely between kits, as suggested previously [24]. Of
note, although the miRvana isolation kit gave the lowest yields
from 1 ml of plasma, ΔCT values were significantly correlated
with the results obtained using the miRNeasy Serum/Plasma
kit and 200 µl of plasma. This kit has been used successfully to
analyse miRNA profiles in a number of other studies [25-27].
We have also demonstrated good correlation between miRNA
profiles of paired samples on two PCR independent array
platforms. Together these results suggest that comparison of
data generated from different extraction methods and analysis
platforms is possible as long as the blood and plasma samples
have been processed to the same protocol. In this study, we
showed that RNA yield and recovery of the spike-in did not
increase significantly with increasing plasma volume,
suggesting that the columns become saturated above 200µl of
plasma and are only capable of isolating a limited quantity of
miRNA [28,29]. One recent study suggested that extraction
from larger volumes of plasma increases the abundance of
blood-borne inhibitors of qRT-PCR [30], which could also have
contributed to the results obtained here. Extraction of miRNA
from 200 µl of plasma is recommended to reduce the volume
involved, minimise blood-borne inhibitors of qRT-PCR and
enable replicate extractions from the same sample.
The use of microRNA PCR array cards is common in the
analysis of circulating miRNAs [31] and has generated
promising results. We have previously analysed cfDNA from
plasma samples stored for >12 years at -80 °C by whole
genome approaches [14] but to our knowledge there are no
prior reports of recovery of miRNA from samples stored for this
length of time. We have shown here that retrospective analysis
of circulating miRNAs by PCR array is possible, and that
results correlated significantly with freshly prepared plasma.
Conclusion
In conclusion, we have shown that careful consideration of
pre-analytical processing is required for optimum preparation of
plasma for CNA analyses. The DNA Blood Mini kit and
Circulating Nucleic Acids kit gave consistently higher yields and
more efficient recovery of cfDNA than the other kits tested, with
equivalent results detected by targeted next generation
sequencing on the Ion PGM platform. The miRNeasy Serum/
Plasma and miRvana kits gave consistent and reproducible
results for miRNA isolation from as little as 200 µl plasma
volume. It was also possible to analyse long term stored
samples, which could enable comparison with other biomarker
data obtained for samples in existing stored biobanks.
However, in the era of the liquid biopsy, care must be taken in
interpretation of miRNA data where the effects of sample
processing may be as significant as disease state.
Supporting Information
Figure S1.  Bioanalyser analysis of cell-free RNA from
different volumes of plasma. Representative Bioanalyser
traces of cell-free RNA obtained from 1 ml, 500 µl or 200 µl of
plasma using the miRNeasy Serum/Plasma kit. Starting
volumes are highlighted above the trace and representative
gels are shown below each trace. Quantities obtained are
shown in the bar graph. Error bar = ±SEM, n = 3.
(TIF)
Figure S2.  Analysis of miRNA profiles on two different
PCR array platforms and effect of long term storage on
miRNA yield. A. Two-tailed Spearman’s correlation analysis of
miRNAs detected in 200 µl of plasma samples using the TLDA
cards A & B (v2.0). miRNAs with CT values >35 were not
included in the analysis. B. Two-tailed Spearman’s correlation
analysis of miRNAs detected in 200 µl of plasma samples
using the Exiqon miRCURY LNA PCR platform. miRNAs with
CT values >35 were not included in the analysis. C. Two-tailed
Spearman’s correlation analysis of ΔCT values for miRNAs
common to both TLDA and miRCURY LNA platforms. miRNAs
with CT values >35 were not included in the analysis. D.
Representative miRCURY LNA PCR array amplification curves
(right hand panels) and melt curves (left hand panels) of
miRNAs with one melt temperature (Tm) (upper panels) and >1
Tm (lower panels). E. Two-tailed Spearman’s correlation
analysis of CT values for miRNAs detected in 200 µl of
metastatic plasma samples comparing 10 pooled freshly
extracted samples, with 10 stored for >12 years. The 95%
confidence interval is shown on the graph (dotted lines). In
total, 140 miRNAs were common to both samples. F.
Spearman’s correlation analysis of ΔCT values for miRNAs
described in E.
(TIF)
Table S1.  Number of reads from two sequencing runs for
4 sets of paired cfDNA samples. This table relates to Figure
2. QIA = QIAamp® DNA Blood Mini kit; CNA = QIAamp® CNA
Kit.
(DOC)
Table S2.  Variants called for the different cfDNA samples.
This table relates to Figure 2. QIA = QIAamp® DNA Blood Mini
kit; CNA = QIAamp® CNA Kit.
(DOC)
Table S3.  CT and ΔCT values obtained from plasma
centrifuged at different speeds. CT and ΔCT values obtained
from TLDA A cards for miRNAs extracted from 200 µl of
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plasma, which had been centrifuged at either 1000g, 2000g or
10000g. This table relates to Figure 4C - E.
(XLS)
Table S4.  CT and ΔCT values obtained from fresh plasma
and plasma stored for >12 years. CT and ΔCT values
obtained from TLDA A cards for miRNAs extracted from 200 µl
of plasma from metastatic breast cancer patients, which had
been freshly extracted or stored at -80 °C for >12 years. This
table relates to Figure S2E & F.
(XLS)
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